文献速递甲状腺核医学核素与放射性配体治疗

罕见嗜酸细胞乳头状甲状腺癌初次(辅助)放射性碘治疗后的长期结局

Long-term outcome of rare oncocytic papillary (Hürthle cell) thyroid carcinoma following (adjuvant) initial radioiodine therapy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-08-13

本研究比较了47例嗜酸细胞乳头状甲状腺癌(OPTC)与516例乳头状甲状腺癌(PTC)患者在中位随访9.9年后甲状腺切除术及初次(辅助)放射性碘治疗(RIT)后的长期预后。OPTC患者诊断时年龄更大、初始肿瘤更大,匹配风险因素后两组疾病特异性生存无显著差异,年龄是疾病特异性生存的独立预后因素。

要点

  • OPTC患者诊断时年龄更大、初始肿瘤更大,与PTC存在显著差异。
  • 匹配风险因素后,OPTC与PTC的长期临床结局无显著差异。
  • 年龄是疾病特异性生存的独立预后因素。

核心结论

  • OPTC在初诊时与PTC在年龄和初始肿瘤大小方面存在显著差异。
  • 经匹配后,OPTC患者接受初次(辅助)RIT后的长期临床结局与PTC相同。

研究设计与样本

  • 研究纳入563例患者,其中OPTC 47例、PTC 516例,中位随访9.9年(范围0.3–23.5年)。
  • 所有患者均接受甲状腺切除术及初次(辅助)RIT,收集人口学、病理、实验室、影像、治疗及随访资料。
  • 采用Cox多因素回归模型识别生存的独立预后因素。

主要发现

  • OPTC患者初诊年龄显著大于PTC患者(55.2±12.3岁 vs 50.3±13.5岁,p=0.016)。
  • OPTC组初始肿瘤尺寸更大(2.8±1.8 cm vs 1.5±1.2 cm,p<0.001)。
  • 匹配前OPTC患者末次随访时更常带病生存(p=0.046),匹配风险因素后该差异消失(p=0.637)。
  • 疾病特异性生存无显著差异,年龄被确定为疾病特异性生存的独立预后因素(HR 1.183;95%CI 1.097–1.276)。
  • OPTC患者复发以远处转移为主且时间更短,但无统计学显著性。

关键数值与推荐

  • 年龄是疾病特异性生存的独立预后因素(HR 1.183;95%CI 1.097–1.276)。

临床怎么用

  • OPTC患者初诊时年龄更大、肿瘤更大,应予以关注。
  • 接受甲状腺切除术及初次(辅助)RIT后,OPTC的长期结局与PTC相当。
  • 年龄可作为疾病特异性生存的预后参考因素。

局限性

  • OPTC样本量较小(47例)。
  • OPTC远处转移复发时间更短的趋势未达统计学显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Oncocytic (Hürthle cell) papillary thyroid carcinoma (OPTC) is a rare variant of the papillary thyroid carcinoma (PTC) which comprises approximately 1 to 11 % of PTC cases. Its clinical course and prognosis have not been comprehensively documented and the clinical outcome remains a controversial issue. Therefore, we investigated the long-term prognosis after thyroidectomy and (adjuvant) initial radioactive iodine therapy (RIT) of OPTC compared to PTC. METHODS: A total of 563 patients (47 with OPTC and 516 with PTC) with a median follow-up of 9.9 (0.3; 23.5) years were studied. All patients underwent thyroidectomy followed by (adjuvant) initial RIT. Data on the patients' demographics, pathology, laboratory findings, imaging studies, treatment, and follow-up including recurrence, and disease-specific survival were collected. Cox's multivariate regression model was used to identify independent prognostic factors for survival. RESULTS: OPTC patients were significantly older (55.2 ± 12.3 years) than PTC patients (50.3 ± 13.5) at the time of initial diagnosis (p value 0.016). Initial tumor size was larger in the OPTC group (2.8 ± 1.8 cm for OPTC patients, 1.5 ± 1.2 cm for PTC patients, p value < 0.001). Before matching, OPTC patients presented more often with evidence of disease at the last visit of follow-up (p value 0.046). However, this difference was not observed anymore after matching for risk factors (p value 0.637). Disease-specific survival did not differ significantly. Age (HR, 1.183; 95% CI, 1.097-1.276) was identified as an independent prognostic factor for disease-specific survival. OPTC patients predominantly showed a recurrence of distant metastasis within a shorter time despite being not statistically significant. CONCLUSION: At initial diagnosis, OPTC shows significant differences in terms of age and initial tumor size compared to PTC. Patients suffering from OPTC present with the same clinical long-term outcome indifferent to PTC after (adjuvant) initial RIT after matching.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wenter V, Jellinek A, Unterrainer M, et al. Long-term outcome of rare oncocytic papillary (Hürthle cell) thyroid carcinoma following (adjuvant) initial radioiodine therapy. Eur J Nucl Med Mol Imaging. 2019. PMID: 31410542. doi:10.1007/s00259-019-04456-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。